Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1868, Issue 2, 2017, Pages 341-358

  Guo, Jianping ^a   Cheng, Ji ^a,b   North, Brian J ^a   Wei, Wenyi ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Aging; Alzheimer's disease; Amyloid; Cell signaling; Tau; Tumorigenesis

Indexed keywords

AMYLOID BETA PROTEIN; HYPOXIA INDUCIBLE FACTOR; LONG UNTRANSLATED RNA; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PEPTIDYL PROLYL CIS TRANS ISOMERASE NIMA INTERACTING 1; SIRTUIN 1; TRANSCRIPTION FACTOR FOXO; SIRT1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR FKHR;

AGING; ALZHEIMER DISEASE; AUTOPHAGY; BRAIN NERVE CELL; CARCINOGENESIS; CELL DAMAGE; DRUG EFFECT; GENE MUTATION; GROWTH REGULATION; HUMAN; HYPOXIA; INFLAMMATION; INSULIN RESISTANCE; MALIGNANT NEOPLASM; METABOLISM; MOLECULAR INTERACTION; MOUSE MODEL; NEUROFIBRILLARY TANGLE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; COMPLICATION; DISEASE MODEL; MAPK SIGNALING; MOUSE; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; AUTOPHAGY; DISEASE MODELS, ANIMAL; FORKHEAD BOX PROTEIN O1; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MAP KINASE SIGNALING SYSTEM; MICE; NEOPLASMS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SIRTUIN 1; TOR SERINE-THREONINE KINASES;

EID: 85025671165     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2017.07.001     Document Type: Review

References (353)

1. Campisi, J., Aging, cellular senescence, and cancer. Annu. Rev. Physiol. 75 (2013), 685–705.
2. Childs, B.G. et al., Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat. Med. 21:12 (2015), 1424–1435.
3. Ugalde, A.P. et al., Aging and chronic DNA damage response activate a regulatory pathway involving miR-29 and p53. EMBO J. 30:11 (2011), 2219–2232.
4. Cuanalo-Contreras, K., Mukherjee, A., Soto, C., Role of protein misfolding and proteostasis deficiency in protein misfolding diseases and aging. Int. J. Cell. Biol., 2013, 2013, 638083.
5. Soto, C., Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4:1 (2003), 49–60.
6. Hamilton, M.L. et al., Does oxidative damage to DNA increase with age?. Proc. Natl. Acad. Sci. U. S. A. 98:18 (2001), 10469–10474.
7. Driver, J.A., Inverse association between cancer and neurodegenerative disease: review of the epidemiologic and biological evidence. Biogerontology 15:6 (2014), 547–557.
8. Loeb, L.A., Loeb, K.R., Anderson, J.P., Multiple mutations and cancer. Proc. Natl. Acad. Sci. U. S. A. 100:3 (2003), 776–781.
9. Knudson, A.G., Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 1:2 (2001), 157–162.
10. Bertram, L., Tanzi, R.E., The genetic epidemiology of neurodegenerative disease. J. Clin. Invest. 115:6 (2005), 1449–1457.
11. Dvoretsky, P.M. et al., Survival time, causes of death, and tumor/treatment-related morbidity in 100 women with ovarian cancer. Hum. Pathol. 19:11 (1988), 1273–1279.
12. Seeley, W.W. et al., Neurodegenerative diseases target large-scale human brain networks. Neuron 62:1 (2009), 42–52.
13. Selkoe, D.J., Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:2 (2001), 741–766.
14. Corbett, A., Smith, J., Ballard, C., New and emerging treatments for Alzheimer's disease. Expert. Rev. Neurother. 12:5 (2012), 535–543.
15. Alzheimer's, A., 2009 Alzheimer's disease facts and figures. Alzheimers Dement. 5:3 (2009), 234–270.
16. Zhu, X. et al., Alzheimer disease, the two-hit hypothesis: an update. Biochim. Biophys. Acta 1772:4 (2007), 494–502.
17. Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:5580 (2002), 353–356.
18. Alonso, A.C., Grundke-Iqbal, I., Iqbal, K., Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat. Med. 2:7 (1996), 783–787.
19. Armstrong, R.A., The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease. Folia Neuropathol. 47:4 (2009), 289–299.
20. Serrano-Pozo, A. et al., Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med., 1(1), 2011, a006189.
21. Albert, M. et al., Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int. J. Neurosci. 57:3-4 (1991), 167–178.
22. Khachaturian, Z.S., Diagnosis of Alzheimer's disease. Arch. Neurol. 42:11 (1985), 1097–1105.
23. Rosen, C. et al., Fluid biomarkers in Alzheimer's disease - current concepts. Mol. Neurodegener., 8, 2013, 20.
24. Ruan, Q. et al., Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty. Mol. Med. Rep. 14:4 (2016), 3184–3198.
25. Scheuner, D. et al., Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2:8 (1996), 864–870.
26. Esquerda-Canals, G. et al., Mouse models of Alzheimer's disease. J. Alzheimers Dis. 57:4 (2017), 1171–1183.
27. Saunders, A.M. et al., Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43:8 (1993), 1467–1472.
28. Licastro, F. et al., Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?. J. Neuroimmunol. 103:1 (2000), 97–102.
29. Mapstone, M. et al., Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Med. 20:4 (2014), 415–418.
30. Hall, A.M., Roberson, E.D., Mouse models of Alzheimer's disease. Brain Res. Bull. 88:1 (2012), 3–12.
31. Sharpless, N.E., Depinho, R.A., The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 5:9 (2006), 741–754.
32. Games, D. et al., Mice as models: transgenic approaches and Alzheimer's disease. J. Alzheimers Dis. 9:3 Suppl (2006), 133–149.
33. Citron, M. et al., Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 3:1 (1997), 67–72.
34. Holcomb, L. et al., Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4:1 (1998), 97–100.
35. De Strooper, B., Iwatsubo, T., Wolfe, M.S., Presenilins and gamma-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harb. Perspect. Med., 2(1), 2012, a006304.
36. Gotz, J. et al., Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J. 14:7 (1995), 1304–1313.
37. Lewis, J. et al., Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25:4 (2000), 402–405.
38. Gotz, J. et al., Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293:5534 (2001), 1491–1495.
39. Yoshiyama, Y. et al., Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53:3 (2007), 337–351.
40. Oddo, S. et al., Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:3 (2003), 409–421.
41. Holtzman, D.M. et al., Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 97:6 (2000), 2892–2897.
42. Bales, K.R. et al., Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 96:26 (1999), 15233–15238.
43. Pastorino, L. et al., The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 440:7083 (2006), 528–534.
44. Kerr, J.S. et al., Mitophagy and Alzheimer's disease: cellular and molecular mechanisms. Trends Neurosci. 40:3 (2017), 151–166.
45. Menzies, F.M. et al., Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities. Neuron 93:5 (2017), 1015–1034.
46. Cheng, J. et al., Autophagy regulates MAVS signaling activation in a phosphorylation-dependent manner in microglia. Cell Death Differ. 24:2 (2017), 276–287.
47. Kim, J. et al., AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 13:2 (2011), 132–141.
48. Plaza-Zabala, A., Sierra-Torre, V., Sierra, A., Autophagy and microglia: novel partners in neurodegeneration and aging. Int. J. Mol. Sci., 2017, 18(3).
49. Coly, P.M. et al., The autophagy machinery: a new player in chemotactic cell migration. Front. Neurosci., 11, 2017, 78.
50. Tanida, I., Ueno, T., Kominami, E., LC3 and autophagy. Methods Mol. Biol. 445 (2008), 77–88.
51. Mathew, R., Karantza-Wadsworth, V., White, E., Role of autophagy in cancer. Nat. Rev. Cancer 7:12 (2007), 961–967.
52. Li, Q., Liu, Y., Sun, M., Autophagy and Alzheimer's disease. Cell. Mol. Neurobiol. 37:3 (2017), 377–388.
53. Zare-Shahabadi, A. et al., Autophagy in Alzheimer's disease. Rev. Neurosci. 26:4 (2015), 385–395.
54. Tian, Y. et al., A small-molecule enhancer of autophagy decreases levels of Abeta and APP-CTF via Atg5-dependent autophagy pathway. FASEB J. 25:6 (2011), 1934–1942.
55. Vingtdeux, V. et al., Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-beta peptide degradation. FASEB J. 25:1 (2011), 219–231.
56. Mizushima, N., A(beta) generation in autophagic vacuoles. J. Cell Biol. 171:1 (2005), 15–17.
57. Yu, W.H. et al., Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: implications for beta-amyloid peptide over-production and localization in Alzheimer's disease. Int. J. Biochem. Cell Biol. 36:12 (2004), 2531–2540.
58. Yang, D.S. et al., Neuronal apoptosis and autophagy cross talk in aging PS/APP mice, a model of Alzheimer's disease. Am. J. Pathol. 173:3 (2008), 665–681.
59. Boland, B. et al., Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J. Neurosci. 28:27 (2008), 6926–6937.
60. Xu, W., Tan, L., Yu, J.T., The role of PICALM in Alzheimer's disease. Mol. Neurobiol. 52:1 (2015), 399–413.
61. Moreau, K. et al., PICALM modulates autophagy activity and tau accumulation. Nat. Commun., 5, 2014, 4998.
62. Pickford, F. et al., The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J. Clin. Invest. 118:6 (2008), 2190–2199.
63. Kaestner, K.H., Knochel, W., Martinez, D.E., Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev. 14:2 (2000), 142–146.
64. Paik, J.H. et al., FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128:2 (2007), 309–323.
65. Coomans de Brachene, A., Demoulin, J.B., FOXO transcription factors in cancer development and therapy. Cell. Mol. Life Sci. 73:6 (2016), 1159–1172.
66. Hu, M.C. et al., IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117:2 (2004), 225–237.
67. Arden, K.C., FoxO: linking new signaling pathways. Mol. Cell 14:4 (2004), 416–418.
68. van der Heide, L.P., Smidt, M.P., Regulation of FoxO activity by CBP/p300-mediated acetylation. Trends Biochem. Sci. 30:2 (2005), 81–86.
69. Motta, M.C. et al., Mammalian SIRT1 represses forkhead transcription factors. Cell 116:4 (2004), 551–563.
70. Zheng, X. et al., Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Genes Dev. 28:13 (2014), 1429–1444.
71. Huang, H. et al., Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc. Natl. Acad. Sci. U. S. A. 102:5 (2005), 1649–1654.
72. Yamagata, K. et al., Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt. Mol. Cell 32:2 (2008), 221–231.
73. Lee, S.S. et al., DAF-16 target genes that control C. elegans life-span and metabolism. Science 300:5619 (2003), 644–647.
74. Finch, C.E., Tanzi, R.E., Genetics of aging. Science 278:5337 (1997), 407–411.
75. Salih, D.A., Brunet, A., FoxO transcription factors in the maintenance of cellular homeostasis during aging. Curr. Opin. Cell Biol. 20:2 (2008), 126–136.
76. Xu, P. et al., JNK regulates FoxO-dependent autophagy in neurons. Genes Dev. 25:4 (2011), 310–322.
77. Eijkelenboom, A., Burgering, B.M., FOXOs: signalling integrators for homeostasis maintenance. Nat. Rev. Mol. Cell Biol. 14:2 (2013), 83–97.
78. Mei, Y. et al., FOXO3a-dependent regulation of Pink1 (Park6) mediates survival signaling in response to cytokine deprivation. Proc. Natl. Acad. Sci. U. S. A. 106:13 (2009), 5153–5158.
79. Gilley, J., Coffer, P.J., Ham, J., FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J. Cell Biol. 162:4 (2003), 613–622.
80. Baar, M.P. et al., Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell 169:1 (2017), 132–147 (e16).
81. Kops, G.J. et al., Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419:6904 (2002), 316–321.
82. Zhang, X. et al., FOXO1 is an essential regulator of pluripotency in human embryonic stem cells. Nat. Cell Biol. 13:9 (2011), 1092–1099.
83. Saxton, R.A., Sabatini, D.M., mTOR signaling in growth, metabolism, and disease. Cell 169:2 (2017), 361–371.
84. Dibble, C.C., Manning, B.D., Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat. Cell Biol. 15:6 (2013), 555–564.
85. Laplante, M., Sabatini, D.M., mTOR signaling at a glance. J. Cell Sci. 122:Pt 20 (2009), 3589–3594.
86. Cornu, M., Albert, V., Hall, M.N., mTOR in aging, metabolism, and cancer. Curr. Opin. Genet. Dev. 23:1 (2013), 53–62.
87. Chong, Z.Z., Maiese, K., Mammalian target of rapamycin signaling in diabetic cardiovascular disease. Cardiovasc. Diabetol., 11, 2012, 45.
88. Sarkar, S., Rubinsztein, D.C., Small molecule enhancers of autophagy for neurodegenerative diseases. Mol. BioSyst. 4:9 (2008), 895–901.
89. Dennis, P.B., Fumagalli, S., Thomas, G., Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Curr. Opin. Genet. Dev. 9:1 (1999), 49–54.
90. Vellai, T. et al., Genetics: influence of TOR kinase on lifespan in C. elegans. Nature, 426(6967), 2003, 620.
91. Selman, C. et al., Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 326:5949 (2009), 140–144.
92. Powers, R.W. 3rd et al., Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev. 20:2 (2006), 174–184.
93. Robida-Stubbs, S. et al., TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. Cell Metab. 15:5 (2012), 713–724.
94. Bjedov, I. et al., Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab. 11:1 (2010), 35–46.
95. Harrison, D.E. et al., Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460:7253 (2009), 392–395.
96. Miller, R.A. et al., Rapamycinmediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell 13:3 (2014 Jun), 468–477.
97. Anisimov, V.N. et al., Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 10:24 (2011), 4230–4236.
98. Miller, R.A. et al., Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J. Gerontol. A Biol. Sci. Med. Sci. 66:2 (2011), 191–201.
99. Drechsel, D.N. et al., Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 3:10 (1992), 1141–1154.
100. Caccamo, A. et al., mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. Aging Cell 12:3 (2013), 370–380.
101. Sontag, J.M., Sontag, E., Protein phosphatase 2A dysfunction in Alzheimer's disease. Front. Mol. Neurosci., 7, 2014, 16.
102. Kickstein, E. et al., Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc. Natl. Acad. Sci. U. S. A. 107:50 (2010), 21830–21835.
103. Pei, J.J. et al., P70 S6 kinase mediates tau phosphorylation and synthesis. FEBS Lett. 580:1 (2006), 107–114.
104. Syntichaki, P., Troulinaki, K., Tavernarakis, N., eIF4E function in somatic cells modulates ageing in Caenorhabditis elegans. Nature 445:7130 (2007), 922–926.
105. Lafay-Chebassier, C. et al., mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease. J. Neurochem. 94:1 (2005), 215–225.
106. Majumder, S. et al., Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One, 6(9), 2011, e25416.
107. Caccamo, A. et al., Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J. Biol. Chem. 285:17 (2010), 13107–13120.
108. Spilman, P. et al., Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One, 5(4), 2010, e9979.
109. Amaral, T. et al., MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition. Eur. J. Cancer 73 (2017), 93–101.
110. Atay, O., Skotheim, J.M., Spatial and temporal signal processing and decision making by MAPK pathways. J. Cell Biol. 216:2 (2017), 317–330.
111. Kim, E.K., Choi, E.J., Compromised MAPK signaling in human diseases: an update. Arch. Toxicol. 89:6 (2015), 867–882.
112. Soares-Silva, M. et al., The mitogen-activated protein kinase (MAPK) pathway: role in immune evasion by trypanosomatids. Front. Microbiol., 7, 2016, 183.
113. Dhillon, A.S. et al., MAP kinase signalling pathways in cancer. Oncogene 26:22 (2007), 3279–3290.
114. Prior, I.A., Lewis, P.D., Mattos, C., A comprehensive survey of Ras mutations in cancer. Cancer Res. 72:10 (2012), 2457–2467.
115. Zakowski, M.F. et al., EGFR mutations in small-cell lung cancers in patients who have never smoked. N. Engl. J. Med. 355:2 (2006), 213–215.
116. Heimberger, A.B. et al., The natural history of EGFR and EGFRvIII in glioblastoma patients. J. Transl. Med., 3, 2005, 38.
117. Davies, H. et al., Mutations of the BRAF gene in human cancer. Nature 417:6892 (2002), 949–954.
118. Pratico, D., Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol. Sci. 29:12 (2008), 609–615.
119. Giraldo, E. et al., Abeta and tau toxicities in Alzheimer's are linked via oxidative stress-induced p38 activation: protective role of vitamin E. Redox Biol. 2 (2014), 873–877.
120. Bach, J.P. et al., The role of CNI-1493 in the function of primary microglia with respect to amyloid-beta. J. Alzheimers Dis. 26:1 (2011), 69–80.
121. Kitazawa, M. et al., Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer's disease model. J. Immunol. 187:12 (2011), 6539–6549.
122. Gan, X. et al., Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer's disease cybrid cell. Biochim. Biophys. Acta 1842:2 (2014), 220–231.
123. Sclip, A. et al., c-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo. Cell Death Dis., 5, 2014, e1019.
124. Chong, Y.H. et al., Effects of the beta-amyloid and carboxyl-terminal fragment of Alzheimer's amyloid precursor protein on the production of the tumor necrosis factor-alpha and matrix metalloproteinase-9 by human monocytic THP-1. J. Biol. Chem. 276:26 (2001), 23511–23517.
125. Kim, C. et al., Amyloid precursor protein processing is separately regulated by protein kinase C and tyrosine kinase in human astrocytes. Neurosci. Lett. 324:3 (2002), 185–188.
126. Frasca, G. et al., Beta-amyloid-activated cell cycle in SH-SY5Y neuroblastoma cells: correlation with the MAP kinase pathway. J. Mol. Neurosci. 22:3 (2004), 231–236.
127. Koistinaho, M. et al., Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc. Natl. Acad. Sci. U. S. A. 99:3 (2002), 1610–1615.
128. Paris, D. et al., Pro-inflammatory effect of freshly solubilized beta-amyloid peptides in the brain. Prostaglandins Other Lipid Mediat. 70:1-2 (2002), 1–12.
129. Veeranna et al., Calpain mediates calcium-induced activation of the erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease. Am. J. Pathol. 165:3 (2004), 795–805.
130. Sanchez, A. et al., p38 MAPK: a mediator of hypoxia-induced cerebrovascular inflammation. J. Alzheimers Dis. 32:3 (2012), 587–597.
131. Munoz, L. et al., A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J. Neuroinflammation, 4, 2007, 21.
132. Zou, L. et al., Inhibiting p38 mitogen-activated protein kinase attenuates cerebral ischemic injury in Swedish mutant amyloid precursor protein transgenic mice. Neural Regen. Res. 7:14 (2012), 1088–1094.
133. Stanley, M., Macauley, S.L., Holtzman, D.M., Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence?. J. Exp. Med. 213:8 (2016), 1375–1385.
134. Peng, Y. et al., Mitochondrial dysfunction precedes depression of AMPK/AKT signaling in insulin resistance induced by high glucose in primary cortical neurons. J. Neurochem. 137:5 (2016), 701–713.
135. Diehl, T., Mullins, R., Kapogiannis, D., Insulin resistance in Alzheimer's disease. Transl. Res. 183 (2017), 26–40.
136. Asghar, A., Sheikh, N., Role of immune cells in obesity induced low grade inflammation and insulin resistance. Cell. Immunol., 2017.
137. Di Meo, S., Iossa, S., Venditti, P., Skeletal muscle insulin resistance: role of mitochondria and other ROS sources. J. Endocrinol. 233:1 (2017), R15–R42.
138. Azziz, R. et al., Polycystic ovary syndrome. Nat. Rev. Dis. Primers, 2, 2016, 16057.
139. Artunc, F. et al., The impact of insulin resistance on the kidney and vasculature. Nat. Rev. Nephrol. 12:12 (2016), 721–737.
140. Tawo, R. et al., The ubiquitin ligase CHIP integrates proteostasis and aging by regulation of insulin receptor turnover. Cell 169:3 (2017), 470–482 (e13).
141. de la Monte, S.M., Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for Alzheimer's disease. Drugs 77:1 (2017), 47–65.
142. Chen, Y. et al., Targeting insulin signaling for the treatment of Alzheimer's disease. Curr. Top. Med. Chem. 16:5 (2016), 485–492.
143. Diehl, T., Mullins, R., Kapogiannis, D., Insulin resistance in Alzheimer's disease. Transl. Res., 2016.
144. Qiu, W.Q. et al., Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 273:49 (1998), 32730–32738.
145. Bedse, G. et al., Aberrant insulin signaling in Alzheimer's disease: current knowledge. Front. Neurosci., 9, 2015, 204.
146. Ma, R. et al., Erythropoietin protects PC12 cells from beta-amyloid(25–35)-induced apoptosis via PI3K/Akt signaling pathway. Neuropharmacology 56:6-7 (2009), 1027–1034.
147. Cross, D.A. et al., Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:6559 (1995), 785–789.
148. Ishiguro, K. et al., Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett. 325:3 (1993), 167–172.
149. Herskovits, A.Z., Guarente, L., SIRT1 in neurodevelopment and brain senescence. Neuron 81:3 (2014), 471–483.
150. Donmez, G., Outeiro, T.F., SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol. Med. 5:3 (2013), 344–352.
151. Igarashi, M., Guarente, L., mTORC1 and SIRT1 cooperate to foster expansion of gut adult stem cells during calorie restriction. Cell 166:2 (2016), 436–450.
152. Kauppinen, A. et al., Antagonistic crosstalk between NF-kappaB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell. Signal. 25:10 (2013), 1939–1948.
153. Rodgers, J.T. et al., Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett. 582:1 (2008), 46–53.
154. Godoy, J.A. et al., Role of Sirt1 during the ageing process: relevance to protection of synapses in the brain. Mol. Neurobiol. 50:3 (2014), 744–756.
155. Coppari, R., Metabolic actions of hypothalamic SIRT1. Trends Endocrinol. Metab. 23:4 (2012), 179–185.
156. Bonda, D.J. et al., The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet Neurol. 10:3 (2011), 275–279.
157. Pasinetti, G.M. et al., Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment. Biochim. Biophys. Acta 1852:6 (2015), 1202–1208.
158. Cao, L. et al., SIRT1 negatively regulates amyloid-beta-induced inflammation via the NF-kappaB pathway. Braz. J. Med. Biol. Res. 46:8 (2013), 659–669.
159. Feng, X. et al., Resveratrol inhibits beta-amyloid-induced neuronal apoptosis through regulation of SIRT1-ROCK1 signaling pathway. PLoS One, 8(3), 2013, e59888.
160. Han, M.K. et al., SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell 2:3 (2008), 241–251.
161. Brunet, A. et al., Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303:5666 (2004), 2011–2015.
162. Min, S.W. et al., Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67:6 (2010), 953–966.
163. Chen, J. et al., SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J. Biol. Chem. 280:48 (2005), 40364–40374.
164. Harris, A.L., Hypoxia—a key regulatory factor in tumour growth. Nat. Rev. Cancer 2:1 (2002), 38–47.
165. Guo, J. et al., pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. Science 353:6302 (2016), 929–932.
166. Safran, M., Kaelin, W.G. Jr., HIF hydroxylation and the mammalian oxygen-sensing pathway. J. Clin. Invest. 111:6 (2003), 779–783.
167. 2 sensing. Science 292:5516 (2001), 464–468.
168. Epstein, A.C. et al., C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:1 (2001), 43–54.
169. Pugh, C.W., Ratcliffe, P.J., Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9:6 (2003), 677–684.
170. Carmeliet, P. et al., Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:6692 (1998), 485–490.
171. Cho, H. et al., On-target efficacy of a HIF-2alpha antagonist in preclinical kidney cancer models. Nature 539:7627 (2016), 107–111.
172. Shen, C. et al., Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene. Cancer Discov. 1:3 (2011), 222–235.
173. Koivunen, P. et al., Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483:7390 (2012), 484–488.
174. Peers, C. et al., Hypoxia and neurodegeneration. Ann. N. Y. Acad. Sci. 1177 (2009), 169–177.
175. Zhang, C.E. et al., Hypoxia-induced tau phosphorylation and memory deficit in rats. Neurodegener. Dis. 14:3 (2014), 107–116.
176. Bazan, N.G., Palacios-Pelaez, R., Lukiw, W.J., Hypoxia signaling to genes: significance in Alzheimer's disease. Mol. Neurobiol. 26:2-3 (2002), 283–298.
177. Green, K.N., Boyle, J.P., Peers, C., Hypoxia potentiates exocytosis and Ca2 + channels in PC12 cells via increased amyloid beta peptide formation and reactive oxygen species generation. J. Physiol. 541:Pt 3 (2002), 1013–1023.
178. Grammas, P. et al., Brain microvasculature and hypoxia-related proteins in Alzheimer's disease. Int. J. Clin. Exp. Pathol. 4:6 (2011), 616–627.
179. Wouters, B.G., Koritzinsky, M., Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 8:11 (2008), 851–864.
180. Guglielmotto, M., Tamagno, E., Danni, O., Oxidative stress and hypoxia contribute to Alzheimer's disease pathogenesis: two sides of the same coin. ScientificWorldJournal 9 (2009), 781–791.
181. Masson, N., Ratcliffe, P.J., Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab., 2(1), 2014, 3.
182. Chong, Z.Z., Li, F., Maiese, K., Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Curr. Neurovasc. Res. 2:5 (2005), 387–399.
183. Wang, Y. et al., Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J. Neurosci. 27:2 (2007), 304–307.
184. Sun, X. et al., Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc. Natl. Acad. Sci. U. S. A. 103:49 (2006), 18727–18732.
185. Mobasheri, A. et al., Hypoxia inducible factor-1 and facilitative glucose transporters GLUT1 and GLUT3: putative molecular components of the oxygen and glucose sensing apparatus in articular chondrocytes. Histol. Histopathol. 20:4 (2005), 1327–1338.
186. Liu, Y. et al., Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett. 582:2 (2008), 359–364.
187. Fang, H. et al., Acute hypoxia promote the phosphorylation of tau via ERK pathway. Neurosci. Lett. 474:3 (2010), 173–177.
188. Zhang, S. et al., Evidence of oxidative stress-induced BNIP3 expression in amyloid beta neurotoxicity. Brain Res. 1138 (2007), 221–230.
189. Mittler, R., Oxidative stress, antioxidants and stress tolerance. Trends Plant Sci. 7:9 (2002), 405–410.
190. Cooke, M.S. et al., Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 17:10 (2003), 1195–1214.
191. Hancock, J.T., Desikan, R., Neill, S.J., Role of reactive oxygen species in cell signalling pathways. Biochem. Soc. Trans. 29:Pt 2 (2001), 345–350.
192. Morgan, M.J., Liu, Z.G., Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res. 21:1 (2011), 103–115.
193. Qutub, A.A., Popel, A.S., Reactive oxygen species regulate hypoxia-inducible factor 1alpha differentially in cancer and ischemia. Mol. Cell. Biol. 28:16 (2008), 5106–5119.
194. Birben, E. et al., Oxidative stress and antioxidant defense. World Allergy Organ. J. 5:1 (2012), 9–19.
195. Kohchi, C. et al., ROS and innate immunity. Anticancer Res. 29:3 (2009), 817–821.
196. Yan, L.J., Positive oxidative stress in aging and aging-related disease tolerance. Redox Biol. 2 (2014), 165–169.
197. Circu, M.L., Aw, T.Y., Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med. 48:6 (2010), 749–762.
198. Son, Y. et al., Mitogen-activated protein kinases and reactive oxygen species: how can ROS activate MAPK pathways?. J. Signal Transduct., 2011, 2011, 792639.
199. Leslie, N.R. et al., Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J. 22:20 (2003), 5501–5510.
200. Ahn, J. et al., Reactive oxygen species-mediated activation of the Akt/ASK1/p38 signaling cascade and p21(Cip1) downregulation are required for shikonin-induced apoptosis. Apoptosis 18:7 (2013), 870–881.
201. Smoot, D.T. et al., Influence of Helicobacter pylori on reactive oxygen-induced gastric epithelial cell injury. Carcinogenesis 21:11 (2000), 2091–2095.
202. Finkel, T., Holbrook, N.J., Oxidants, oxidative stress and the biology of ageing. Nature 408:6809 (2000), 239–247.
203. Van Raamsdonk, J.M., Hekimi, S., Deletion of the mitochondrial superoxide dismutase sod-2 extends lifespan in Caenorhabditis elegans. PLoS Genet., 5(2), 2009, e1000361.
204. Melov, S. et al., Lifespan extension and rescue of spongiform encephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase mimetics. J. Neurosci. 21:21 (2001), 8348–8353.
205. Nunomura, A. et al., Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60:8 (2001), 759–767.
206. Manczak, M. et al., Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 15:9 (2006), 1437–1449.
207. Lin, M.T., Beal, M.F., Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:7113 (2006), 787–795.
208. Bondy, S.C., Guo-Ross, S.X., Truong, A.T., Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid. Brain Res. 799:1 (1998), 91–96.
209. Rodrigo-Moreno, A., Poschenrieder, C., Shabala, S., Transition metals: a double edge sward in ROS generation and signaling. Plant Signal. Behav., 8(3), 2013, e23425.
210. Muller, M., Cheung, K.H., Foskett, J.K., Enhanced ROS generation mediated by Alzheimer's disease presenilin regulation of InsP3R Ca2 + signaling. Antioxid. Redox Signal. 14:7 (2011), 1225–1235.
211. Lovell, M.A., Markesbery, W.R., Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid. Arch. Neurol. 58:3 (2001), 392–396.
212. Huang, X. et al., The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38:24 (1999), 7609–7616.
213. Yatin, S.M., Varadarajan, S., Butterfield, D.A., Vitamin E prevents Alzheimer's amyloid beta-peptide (1–42)-induced neuronal protein oxidation and reactive oxygen species production. J. Alzheimers Dis. 2:2 (2000), 123–131.
214. Barnes, D.E., Yaffe, K., Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 353:9 (2005), 951–952 (author reply 951-2).
215. Haynes, C.M., Titus, E.A., Cooper, A.A., Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death. Mol. Cell 15:5 (2004), 767–776.
216. Huang, X. et al., Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann. N. Y. Acad. Sci. 1012 (2004), 153–163.
217. Smith, M.A. et al., Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J. Alzheimers Dis. 19:1 (2010), 363–372.
218. House, E. et al., Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J. Alzheimers Dis. 6:3 (2004), 291–301.
219. Cherny, R.A. et al., Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:3 (2001), 665–676.
220. Guo, C. et al., Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. Neurobiol. Aging 34:2 (2013), 562–575.
221. Montine, T.J. et al., Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic. Biol. Med. 33:5 (2002), 620–626.
222. Cairns, R.A., Harris, I.S., Mak, T.W., Regulation of cancer cell metabolism. Nat. Rev. Cancer 11:2 (2011), 85–95.
223. Shimobayashi, M., Hall, M.N., Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat. Rev. Mol. Cell Biol. 15:3 (2014), 155–162.
224. Canto, C. et al., AMPK regulates energy expenditure by modulating NAD + metabolism and SIRT1 activity. Nature 458:7241 (2009), 1056–1060.
225. Alberti, K.G. et al., The metabolic syndrome—a new worldwide definition. Lancet 366:9491 (2005), 1059–1062.
226. Kinnaird, A. et al., Metabolic control of epigenetics in cancer. Nat. Rev. Cancer 16:11 (2016), 694–707.
227. Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:5930 (2009), 1029–1033.
228. Choi, E.S. et al., Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma. Eur. J. Nucl. Med. Mol. Imaging 40:12 (2013), 1836–1842.
229. Brown, G.K. et al., Pyruvate dehydrogenase deficiency. J. Med. Genet. 31:11 (1994), 875–879.
230. Lei, K.J. et al., Mutations in the glucose-6-phosphatase gene that cause glycogen storage disease type 1a. Science 262:5133 (1993), 580–583.
231. Cani, P.D. et al., Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57:6 (2008), 1470–1481.
232. Zhu, X. et al., Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. J. Alzheimers Dis. 9:2 (2006), 147–153.
233. Hoglinger, G.U. et al., The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J. Neurochem. 95:4 (2005), 930–939.
234. Crouch, P.J. et al., Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J. Neurosci. 25:3 (2005), 672–679.
235. Hirai, K. et al., Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 21:9 (2001), 3017–3023.
236. Parker, W.D. Jr., Filley, C.M., Parks, J.K., Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 40:8 (1990), 1302–1303.
237. Dumont, M., Beal, M.F., Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic. Biol. Med. 51:5 (2011), 1014–1026.
238. Wood, J.G. et al., Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430:7000 (2004), 686–689.
239. Colman, R.J. et al., Caloric restriction reduces age-related and all-cause mortality in rhesus monkeys. Nat. Commun., 5, 2014, 3557.
240. Colman, R.J. et al., Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325:5937 (2009), 201–204.
241. Mattison, J.A. et al., Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 489:7415 (2012), 318–321.
242. Halagappa, V.K. et al., Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 26:1 (2007), 212–220.
243. Hardie, D.G., Ross, F.A., Hawley, S.A., AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13:4 (2012), 251–262.
244. Cheng, J. et al., Functional characterization of AMP-activated protein kinase signaling in tumorigenesis. Biochim. Biophys. Acta 1866:2 (2016), 232–251.
245. Thornton, C. et al., AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid beta-peptide exposure. Biochem. J. 434:3 (2011), 503–512.
246. Vingtdeux, V. et al., AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol. 121:3 (2011), 337–349.
247. Chen, Y. et al., Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc. Natl. Acad. Sci. U. S. A. 106:10 (2009), 3907–3912.
248. Salminen, A. et al., AMP-activated protein kinase: a potential player in Alzheimer's disease. J. Neurochem. 118:4 (2011), 460–474.
249. Cho, M.H. et al., Autophagy in microglia degrades extracellular beta-amyloid fibrils and regulates the NLRP3 inflammasome. Autophagy 10:10 (2014), 1761–1775.
250. Chaplin, D.D., Overview of the immune response. J. Allergy Clin. Immunol. 125:2 Suppl. 2 (2010), S3–23.
251. Hotamisligil, G.S., Inflammation and metabolic disorders. Nature 444:7121 (2006), 860–867.
252. Coussens, L.M., Werb, Z., Inflammation and cancer. Nature 420:6917 (2002), 860–867.
253. Ostrand-Rosenberg, S., Sinha, P., Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182:8 (2009), 4499–4506.
254. Wang, C.Y., Mayo, M.W., Baldwin, A.S. Jr., TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274:5288 (1996), 784–787.
255. Darnell, J.E. Jr., Kerr, I.M., Stark, G.R., Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:5164 (1994), 1415–1421.
256. Tamura, T. et al., The IRF family transcription factors in immunity and oncogenesis. Annu. Rev. Immunol. 26 (2008), 535–584.
257. Miyamoto, K. et al., Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 1:1 (2007), 101–112.
258. van Grevenynghe, J. et al., Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. J. Clin. Invest. 121:10 (2011), 3877–3888.
259. Luke, J.J., Ott, P.A., Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?. Expert. Opin. Pharmacother. 14:18 (2013), 2457–2462.
260. Heneka, M.T. et al., Neuroinflammation in Alzheimer's disease. Lancet Neurol. 14:4 (2015), 388–405.
261. Twine, N.A. et al., Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer's disease. PLoS One, 6(1), 2011, e16266.
262. McGeer, P.L., McGeer, E.G., The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 126:4 (2013), 479–497.
263. Meraz-Rios, M.A. et al., Inflammatory process in Alzheimer's Disease. Front. Integr. Neurosci., 7, 2013, 59.
264. Cramer, P.E. et al., ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335:6075 (2012), 1503–1506.
265. Matsuoka, Y. et al., Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 158:4 (2001), 1345–1354.
266. Jantzen, P.T. et al., Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 22:6 (2002), 2246–2254.
267. Reed-Geaghan, E.G. et al., CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J. Neurosci. 29:38 (2009), 11982–11992.
268. Valerio, A. et al., NF-kappaB pathway: a target for preventing beta-amyloid (Abeta)-induced neuronal damage and Abeta42 production. Eur. J. Neurosci. 23:7 (2006), 1711–1720.
269. Akama, K.T. et al., Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proc. Natl. Acad. Sci. U. S. A. 95:10 (1998), 5795–5800.
270. Bell, K.A. et al., MAPK recruitment by beta-amyloid in organotypic hippocampal slice cultures depends on physical state and exposure time. J. Neurochem. 91:2 (2004), 349–361.
271. Limatola, C., Ransohoff, R.M., Modulating neurotoxicity through CX3CL1/CX3CR1 signaling. Front. Cell. Neurosci., 8, 2014, 229.
272. Bhaskar, K. et al., Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68:1 (2010), 19–31.
273. Rubio-Perez, J.M., Morillas-Ruiz, J.M., A review: inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal, 2012, 2012, 756357.
274. Wang, W.Y. et al., Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. Ann. Transl. Med., 3(10), 2015, 136.
275. Hartlage-Rubsamen, M. et al., Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent. Glia 41:2 (2003), 169–179.
276. Gasparini, L., Ongini, E., Wenk, G., Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J. Neurochem. 91:3 (2004), 521–536.
277. Stewart, W.F. et al., Risk of Alzheimer's disease and duration of NSAID use. Neurology 48:3 (1997), 626–632.
278. Lemere, C.A. et al., Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol. 20:11 (2001), 705–711.
279. Morgan, D. et al., A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:6815 (2000), 982–985.
280. Dodart, J.C. et al., Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5:5 (2002), 452–457.
281. Zheng, Y., Wang, Z., Zhou, Z., miRNAs: novel regulators of autoimmunity-mediated pancreatic beta-cell destruction in type 1 diabetes. Cell. Mol. Immunol., 2017.
282. Basavaraju, M., de Lencastre, A., Alzheimer's disease: presence and role of microRNAs. Biomol. Concepts 7:4 (2016), 241–252.
283. Wen, M.M., Getting miRNA therapeutics into the target cells for neurodegenerative diseases: a mini-review. Front. Mol. Neurosci., 9, 2016, 129.
284. Dickson, J.R. et al., Alternative polyadenylation and miR-34 family members regulate tau expression. J. Neurochem. 127:6 (2013), 739–749.
285. Hernandez-Rapp, J., Rainone, S., Hebert, S.S., MicroRNAs underlying memory deficits in neurodegenerative disorders. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 73 (2017), 79–86.
286. Hebert, S.S. et al., Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc. Natl. Acad. Sci. U. S. A. 105:17 (2008), 6415–6420.
287. Muller, M. et al., MicroRNA-29a is a candidate biomarker for Alzheimer's disease in cell-free cerebrospinal fluid. Mol. Neurobiol. 53:5 (2016), 2894–2899.
288. Kung, J.T., Colognori, D., Lee, J.T., Long noncoding RNAs: past, present, and future. Genetics 193:3 (2013), 651–669.
289. Adams, B.D. et al., Targeting noncoding RNAs in disease. J. Clin. Invest. 127:3 (2017), 761–771.
290. Wan, P., Su, W., Zhuo, Y., The role of long noncoding RNAs in neurodegenerative diseases. Mol. Neurobiol. 54:3 (2017), 2012–2021.
291. Chen, Y., Zhou, J., LncRNAs: macromolecules with big roles in neurobiology and neurological diseases. Metab. Brain Dis. 32:2 (2017), 281–291.
292. Quinn, J.J., Chang, H.Y., Unique features of long non-coding RNA biogenesis and function. Nat. Rev. Genet. 17:1 (2016), 47–62.
293. Modarresi, F. et al., Knockdown of BACE1-AS nonprotein-coding transcript modulates beta-amyloid-related hippocampal neurogenesis. Int. J. Alzheimers Dis., 2011, 2011, 929042.
294. Faghihi, M.A. et al., Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat. Med. 14:7 (2008), 723–730.
295. Mus, E., Hof, P.R., Tiedge, H., Dendritic BC200 RNA in aging and in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 104:25 (2007), 10679–10684.
296. Wu, P. et al., Roles of long noncoding RNAs in brain development, functional diversification and neurodegenerative diseases. Brain Res. Bull. 97 (2013), 69–80.
297. Dupont, C., Armant, D.R., Brenner, C.A., Epigenetics: definition, mechanisms and clinical perspective. Semin. Reprod. Med. 27:5 (2009), 351–357.
298. Qazi, T.J. et al., Epigenetics in Alzheimer's disease: perspective of DNA methylation. Mol. Neurobiol., 2017.
299. Klein, H.U., Bennett, D.A., De Jager, P.L., The epigenome in Alzheimer's disease: current state and approaches for a new path to gene discovery and understanding disease mechanism. Acta Neuropathol. 132:4 (2016), 503–514.
300. Sanchez-Mut, J.V., Graff, J., Epigenetic alterations in Alzheimer's disease. Front. Behav. Neurosci., 9, 2015, 347.
301. Lardenoije, R. et al., The epigenetics of aging and neurodegeneration. Prog. Neurobiol. 131 (2015), 21–64.
302. Hodgson, N. et al., Soluble oligomers of amyloid-beta cause changes in redox state, DNA methylation, and gene transcription by inhibiting EAAT3 mediated cysteine uptake. J. Alzheimers Dis. 36:1 (2013), 197–209.
303. Sung, H.Y. et al., Amyloid protein-mediated differential DNA methylation status regulates gene expression in Alzheimer's disease model cell line. Biochem. Biophys. Res. Commun. 414:4 (2011), 700–705.
304. Lunnon, K. et al., Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. Nat. Neurosci. 17:9 (2014), 1164–1170.
305. De Jager, P.L. et al., Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat. Neurosci. 17:9 (2014), 1156–1163.
306. Rumbaugh, G. et al., Pharmacological selectivity within class I histone deacetylases Predicts effects on synaptic function and memory rescue. Neuropsychopharmacology 40:10 (2015), 2307–2316.
307. Graff, J. et al., An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483:7388 (2012), 222–226.
308. Zhou, X.Z., Lu, K.P., The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target. Nat. Rev. Cancer 16:7 (2016), 463–478.
309. Rustighi, A. et al., PIN1 in breast development and cancer: a clinical perspective. Cell Death Differ. 24:2 (2017), 200–211.
310. Lu, Z., Hunter, T., Prolyl isomerase Pin1 in cancer. Cell Res. 24:9 (2014), 1033–1049.
311. Lin, C.H. et al., Landscape of Pin1 in the cell cycle. Exp. Biol. Med. (Maywood) 240:3 (2015), 403–408.
312. Blair, L.J. et al., The emerging role of peptidyl-prolyl isomerase chaperones in tau oligomerization, amyloid processing, and Alzheimer's disease. J. Neurochem. 133:1 (2015), 1–13.
313. Lu, P.J. et al., The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399:6738 (1999), 784–788.
314. Ma, S.L. et al., Prolyl isomerase Pin1 promotes amyloid precursor protein (APP) turnover by inhibiting glycogen synthase kinase-3beta (GSK3beta) activity: novel mechanism for Pin1 to protect against Alzheimer disease. J. Biol. Chem. 287:10 (2012), 6969–6973.
315. Cazarim Mde, S. et al., Perspectives for treating Alzheimer's disease: a review on promising pharmacological substances. Sao Paulo Med. J. 134:4 (2016), 342–354.
316. Grimm, A., Eckert, A., Brain aging and neurodegeneration: from a mitochondrial point of view. J. Neurochem., 2017.
317. Blagosklonny, M.V., Validation of anti-aging drugs by treating age-related diseases. Aging (Albany NY) 1:3 (2009), 281–288.
318. Lamming, D.W. et al., Rapalogs and mTOR inhibitors as anti-aging therapeutics. J. Clin. Invest. 123:3 (2013), 980–989.
319. Richardson, A. et al., How longevity research can lead to therapies for Alzheimer's disease: the rapamycin story. Exp. Gerontol. 68 (2015), 51–58.
320. Awasthi, M. et al., Alzheimer's disease: an overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products. J. Neurol. Sci. 361 (2016), 256–271.
321. Braidy, N. et al., Sirtuins in cognitive ageing and Alzheimer's disease. Curr. Opin. Psychiatry 25:3 (2012), 226–230.
322. Albani, D. et al., Neuroprotective properties of resveratrol in different neurodegenerative disorders. Biofactors 36:5 (2010), 370–376.
323. Bachurin, S.O., Bovina, E.V., Ustyugov, A.A., Drugs in clinical trials for Alzheimer's disease: the major trends. Med. Res. Rev., 2017.
324. Kennedy, M.E. et al., The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer's disease patients. Sci. Transl. Med., 8(363), 2016, 363ra150.
325. Hawkes, N., Merck ends trial of potential Alzheimer's drug verubecestat. BMJ, 356, 2017, j845.
326. Cebers, G. et al., AZD3293: pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer's disease. J. Alzheimers Dis. 55:3 (2017), 1039–1053.
327. Kummar, S. et al., Clinical activity of the gamma-secretase inhibitor PF-03084014 in adults with Desmoid tumors (aggressive fibromatosis). J. Clin. Oncol., 2017, JCO2016711994.
328. Papayannidis, C. et al., A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J., 5, 2015, e350.
329. Carrera, I. et al., Validating Immunotherapy in Alzheimer's disease: The EB101 Vaccine. Curr. Pharm. Des. 22:7 (2016), 849–858.
330. Barrera-Ocampo, A., Lopera, F., Amyloid-beta immunotherapy: the hope for Alzheimer disease?. Colomb. Med. 47:4 (2016), 203–212.
331. Busche, M.A. et al., Decreased amyloid-beta and increased neuronal hyperactivity by immunotherapy in Alzheimer's models. Nat. Neurosci. 18:12 (2015), 1725–1727.
332. Schroeder, S.K. et al., Tau-directed immunotherapy: a promising strategy for treating Alzheimer's disease and other tauopathies. J. NeuroImmune Pharmacol. 11:1 (2016), 9–25.
333. Panza, F. et al., Tau-centric targets and drugs in clinical development for the treatment of Alzheimer's disease. Biomed. Res. Int., 2016, 2016, 3245935.
334. Waite, L.M., Treatment for Alzheimer's disease: has anything changed?. Aust. Prescr. 38:2 (2015), 60–63.
335. Heckman, P.R., Wouters, C., Prickaerts, J., Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview. Curr. Pharm. Des. 21:3 (2015), 317–331.
336. Liu, S.L. et al., The role of Cdk5 in Alzheimer's disease. Mol. Neurobiol. 53:7 (2016), 4328–4342.
337. Ong, W.Y. et al., Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders. ACS Chem. Neurosci. 6:6 (2015), 814–831.
338. Games, D. et al., Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373:6514 (1995), 523–527.
339. Sturchler-Pierrat, C. et al., Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U. S. A. 94:24 (1997), 13287–13292.
340. Mucke, L. et al., High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20:11 (2000), 4050–4058.
341. Janus, C. et al., A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408:6815 (2000), 979–982.
342. Rockenstein, E. et al., Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1–42). J. Neurosci. Res. 66:4 (2001), 573–582.
343. Duff, K. et al., Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383:6602 (1996), 710–713.
344. Andorfer, C. et al., Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86:3 (2003), 582–590.
345. Zhang, B. et al., Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J. Neurosci. 24:19 (2004), 4657–4667.
346. Allen, B. et al., Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22:21 (2002), 9340–9351.
347. Santacruz, K. et al., Tau suppression in a neurodegenerative mouse model improves memory function. Science 309:5733 (2005), 476–481.
348. Bales, K.R. et al., Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17:3 (1997), 263–264.
349. Dodart, J.C. et al., Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 102:4 (2005), 1211–1216.
350. Liou, Y.C. et al., Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 424:6948 (2003), 556–561.
351. Borchelt, D.R. et al., Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19:4 (1997), 939–945.
352. Lewis, J. et al., Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:5534 (2001), 1487–1491.
353. Graybeal, J.J. et al., Human ApoE epsilon4 alters circadian rhythm activity, IL-1beta, and GFAP in CRND8 mice. J. Alzheimers Dis. 43:3 (2015), 823–834.